Skip to content

AVA-ROSE

Active Private limited companyfounded 2025active for 1 yearBurgemeester J-L Thysplein 1B, 1090 JetteKBO/BCE: BE 1022.725.141

Lifetime

1 annual account with figures
peak of €50,368 in 2025
€50,368 
lowest -€3,001 in 2025
-€3,001 
peak of -€2,001 in 2025
-€2,001 
€383,860 
Board1 name since 2025
1 director
Documentsfilings and deeds
01-07-202630 days before the deadline
2025micro format
UBO non-compliance 31-10Loss of €3,001UBO strike-off withdrawn 05-12Incorporation 29-041 establishment registeredFirst year with figures

Key points

from the 2025 annual accounts

Equity

-€2,001
2025

Debts exceed assets in financial year 2025.

Turnover

≈ €240,000 estimated

The micro format states no turnover.

Debts

€383,860 101% of the balance sheet
Financial debts 62%Suppliers 20%Taxes and wages 2%Other 16%

Of this, €163,899 falls due within a year.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 230 companies had the same profile as AVA-ROSE has now. Each dot is one company, two years later.

96.1%
were still trading
2.2%
stopped another way
1.7%
went bankrupt
  • Micro
  • under 2 years old
  • negative equity
  • a small loss
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 230 companies, not a prediction for AVA-ROSE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 25-04-2025
  • 100 sharesdeed of 29-04-2025
Board & ownership

Recent changes

UBO strike-off withdrawn effective 24-11-2025 · KBO administration
Registered in the Peppol Directory Reachable for e-invoices through 0208:1022725141
UBO non-compliance effective 22-10-2025 · KBO administration
First establishment Apotheek Laerbeek pharma, Burgemeester J-L Thysplein 1B, Jette
All 6 events

Comparable companies

same main activity, similar in size and age
Company
AVA-ROSE Jette €381,859 €50,368 -0.5% -
Kesters Pharma Invest Houthalen-Helchteren €469,134 €51,798 8.4% -
Astgen Leboeuf Woluwe-Saint-Lambert €378,915 €79,684 18.5% -
LINDA PHARMA Etterbeek €258,710 €60,555 16.9% -
Pharmacie de Gimnée Doische €365,085 €32,323 7.9% -
PHARMACIE MOLINVAUX Liège €349,144 €69,529 20.1% -
APOTHEEK DECKERS Antwerp €429,684 €89,485 15.4% -

These companies have the same main activity as AVA-ROSE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €259,000 and €469,000, founded between 2023 and 2025.

Official details

Source: KBO
Status
Active since 25-04-2025Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 1 other
Establishment unit
2.374.898.7081090 Jette, since 01-07-2025
Financial year end
31 December
Peppol
Reachable since 03-12-2025
Company details

Annual accounts 2025

€381,859
Employeeson 31-12-2025
1
Filing
Filed on 01-07-2026, 30 days before the end of the filing period
Financials

Insights on AVA-ROSE

The 2025 annual accounts show negative equity of -€2,001 and a net result of -€3,001. Its solvency ranks better than 22% of 25,428 sector peers (NACE 47) in financial year 2025.

The company has been active since 2025 and the Belgian Official Gazette contains no insolvency signals. The KBO does carry 2 administrative register entries.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about AVA-ROSE

What is the company number of AVA-ROSE?
The company number of AVA-ROSE is 1022.725.141. The VAT number is the same number with BE in front: BE 1022.725.141.
Where is AVA-ROSE based?
The registered office is at Burgemeester J-L Thysplein 1B, 1090 Jette.Company details
What does AVA-ROSE do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of AVA-ROSE?
AVA-ROSE is a private limited company (BV).
When was AVA-ROSE founded?
AVA-ROSE was founded on 25-04-2025.
Is AVA-ROSE still active?
Yes, AVA-ROSE is an active enterprise in the KBO register.
How many employees does AVA-ROSE have?
AVA-ROSE had an average of 0.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of AVA-ROSE?
The turnover in financial year 2025 is about €240,000. This figure is estimated from the gross margin of €50,368 and 56 comparable companies (NACE 477). It probably lies between €130,000 and €360,000.
Is AVA-ROSE profitable?
In financial year 2025, AVA-ROSE made a loss of €3,001.
Where can I find the annual accounts of AVA-ROSE?
AVA-ROSE filed 1 annual account with the National Bank of Belgium, for financial year 2025.
When are the next annual accounts of AVA-ROSE due?
AVA-ROSE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.